Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi France confirms atorvastatin accord with Pfizer

This article was originally published in Scrip

Executive Summary

Sanofi France has confirmed to Scrip that it has signed a licensing deal with Pfizer to manufacture the cholesterol lowering blockbuster atorvastatin in France. The company further confirmed that it will not launch Tahor, the name for its version of the drug, until after the Lipitor patent has expired fully in France on 7 May 2012. While the US patent for Lipitor expires in November 2011, Pfizer secured a six month extension to its European exclusivity through a paediatric supplementary protection certificate.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts